Neurogene Inc. — Director's Dealing 2014

Mar 10, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AQUINOX PHARMACEUTICALS, INC (AQXP)
CIK: 0001404644
Period of Report: 2014-03-06

Reporting Person: LEVITT DANIEL J (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-03-06	Stock Option (Right to Buy)	$11.00	A	8333	Acquired	2024-03-05	Common Stock (8333)	Direct

Footnotes

F1: The shares subject to this option shall vest in equal annual installments, at a rate of 1/3rd of the total number of shares on the one-year anniversary of the grant date, 1/3rd of the total number of shares on the second-year anniversary of the grant date, and 1/3rd of the total number of shares on the third-year anniversary of the grant date.

F2: Includes (i) 8,333 shares issuable upon exercise of an option grant pursuant to the issuer's 2014 Equity Incentive Plan (the "2014 Plan") and (ii) 11,718 option securities issuable upon exercise of an option granted pursuant to the issuer's Joint Canadian Stock Option Plan (the "2006 Plan"). Each option under the 2014 Plan is exercisable for shares of common stock. Each option security granted under the 2006 Plan is exercisable for an "option security". Prior to the closing of the issuer's initial public offering, an option security is comprised of one common exchangeable share and one special voting share of Aquinox Pharmaceuticals Inc., a corporation under the Canadian Business Corporations Act. Following the closing of the issuer's initial public offering, an option security will be comprised of one share of the issuer's common stock.